Tourmaline Bio, Inc. (TRML)
USD 19.87
(-9.1%)
USD 19.87
(-9.1%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 33 Thousand | 6000.00 | 623 Thousand | 447 Thousand | 379 Thousand |
| Gross Profit | -33 Thousand | -6000.00 | -623 Thousand | -447 Thousand | -379 Thousand |
| Operating Expenses | 45.4 Million | 19.7 Million | 904.00 | 22.23 Million | 17.99 Million |
| Selling, General and Administrative Expenses | 13.04 Million | 2.17 Million | 692.00 | 6.95 Million | 4.63 Million |
| Research and Development Expenses | 32.36 Million | 17.52 Million | 212.00 | 15.27 Million | 13.36 Million |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 45.4 Million | 19.7 Million | 904.00 | 22.68 Million | 18.37 Million |
| Operating Income | -45.4 Million | -19.7 Million | -904.00 | -22.68 Million | -18.37 Million |
| Interest Expense | - | - | - | 23 Thousand | - |
| Income Tax Expense | - | - | -47.21 Million | - | - |
| Earnings before Tax | -42.12 Million | -19.7 Million | -904.00 | -22.7 Million | -18.15 Million |
| Net Income | -42.12 Million | -19.7 Million | -904.00 | -22.7 Million | -18.15 Million |
| Earnings Per Share Basic | -8.87 | -0.97 | -0.00 | -33.97 | -4.39 |
| Earnings Per Share Diluted | -8.87 | -0.97 | -0.00 | -33.97 | -4.39 |
| Weighted Average Shares Outstanding | 4.74 Million | 20.33 Million | 10.87 Million | 668.5 Thousand | 4.13 Million |
| Weighted Average Shares Outstanding (Diluted) | 4.74 Million | 20.33 Million | 10.87 Million | 668.5 Thousand | 4.13 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -45.37 Million | -19.69 Million | -46.88 Million | -22.23 Million | -17.77 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.27 Million | - | - |
| Cost of Revenue | 10 Thousand | 10 Thousand | 33 Thousand | 1.13 Million | 238 Thousand | 261 Thousand |
| Gross Profit | -10 Thousand | -10 Thousand | -33 Thousand | 1.13 Million | -238 Thousand | -261 Thousand |
| Operating Expenses | 21.96 Million | 17.51 Million | 45.4 Million | 6.31 Million | 9.38 Million | 16.37 Million |
| Selling, General and Administrative Expenses | 6.22 Million | 6.14 Million | - | -8.28 Million | 9.11 Million | 1.92 Million |
| Research and Development Expenses | 15.73 Million | 11.37 Million | - | 14.59 Million | 267 Thousand | 14.45 Million |
| Other Expenses | 4.48 Million | 4.2 Million | 3.28 Million | - | - | 245 Thousand |
| Cost and Expenses | 21.97 Million | 17.51 Million | 45.4 Million | 6.31 Million | 9.38 Million | 16.37 Million |
| Operating Income | -21.97 Million | -17.51 Million | -45.4 Million | 4.1 Million | -8.93 Million | -16.37 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | - | 6.36 Million | -2.36 Million | -244.75 Thousand |
| Earnings before Tax | -17.48 Million | -13.31 Million | -42.12 Million | 2.12 Million | -7.01 Million | -16.12 Million |
| Net Income | -17.48 Million | -13.31 Million | -42.12 Million | 2.12 Million | -7.01 Million | -16.12 Million |
| Earnings Per Share Basic | -0.68 | -0.55 | - | -0.81 | -0.34 | -1.30 |
| Earnings Per Share Diluted | -0.68 | -0.55 | - | -0.81 | -0.34 | -1.30 |
| Weighted Average Shares Outstanding | 25.72 Million | 24.08 Million | 20.33 Million | 16 Million | 20.33 Million | 12.41 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.72 Million | 24.08 Million | 20.33 Million | 16 Million | 20.33 Million | 12.41 Million |
| Gross Margin | - | - | - | 0.50 | - | - |
| EBIT Margin | - | - | - | -2.78 | - | - |
| Profit Margin | - | - | - | 0.93 | - | - |
| EBITDA | -21.96 Million | -17.5 Million | - | -6.31 Million | -8.7 Million | -16.36 Million |
| Earnings Before Tax Margin | - | - | - | 1.80 | - | - |
MBLY3
SBC
002780
LBS
KEPEN
ELI